MGC Pharmaceuticals has been collaborating with the University of Sydney Business School community engagement program in the production of a medical cannabis white paper.

The paper, titled Clinical Evidence for Medical Cannabis: Epilepsy, Cancer and Multiple Sclerosis examines existing evidence supporting the efficacy of medical cannabis.

This second collaboration between the two also examines medical cannabis applicability to relieve associated symptoms for a range of health related issues, including pain nausea and loss of appetite.

For medical cannabis to become a trusted treatment option among medical professionals and patients alike, there needs to be rigorous clinical evidence supporting efficacy,” said MGC co-founder and managing director Nativ Segev.

“We believe in the potential of medical cannabis more than most, but that belief needs to be proven in the lab under strict conditions.”

MGC has provided support and expertise developed in the Israeli medical cannabis industry to the University of Sydney during the study,...